A 52-year-old man with a 10-year history of cirrhosis (Child-Pugh Class C, MELD 28) presents with hematemesis. Endoscopy confirms bleeding esophageal varices. After successful variceal ligation, he is started on prophylactic antibiotics and vasoconstrictors. Pre-procedure laboratory results: INR 2.8, aPTT 42 sec (control 28 sec), Platelet count 45,000/μL, Fibrinogen 120 mg/dL (normal 200–400), PT 18 sec (control 12 sec). Which coagulation abnormality is MOST important to correct before any elective procedure in this patient?

Explanation

## Coagulation Management in Cirrhosis: Prioritizing INR Correction ### Understanding Cirrhotic Coagulopathy **Key Point:** Cirrhosis causes a **complex coagulopathy** with simultaneous defects in procoagulant synthesis (factors II, V, VII, IX, X), anticoagulant synthesis (protein C, protein S), and platelet dysfunction. The INR is the MOST clinically relevant marker and should be the primary target for correction. ### Why INR Correction Is Priority **High-Yield:** In cirrhosis: - **Liver synthesizes ALL vitamin K-dependent factors** (II, VII, IX, X) and factor V - **INR reflects the net balance** of procoagulant and anticoagulant factors (protein C, protein S also reduced) - **INR >1.5 is associated with increased bleeding risk** in cirrhotic patients - **Vitamin K deficiency** is common due to cholestasis and poor absorption - **Fresh frozen plasma (FFP)** provides immediate replacement of all coagulation factors ### Comparison of Coagulation Abnormalities in This Patient | Parameter | Finding | Clinical Significance | Correction Priority | |-----------|---------|----------------------|---------------------| | **INR** | 2.8 (↑↑) | Reflects hepatic synthetic dysfunction; direct bleeding risk | **1st — HIGHEST** | | **aPTT** | 42 sec (↑) | Reflects deficiency of factors II, IX, X, XII; less specific | 2nd | | **Platelets** | 45,000/μL | Cirrhosis causes splenic sequestration; transfusion needed only if <20,000 or active bleeding | 3rd | | **Fibrinogen** | 120 mg/dL | Mild reduction; synthesis impaired but rarely <100; transfuse only if <80 mg/dL | 4th | **Clinical Pearl:** The **"rebalanced coagulopathy" concept** in cirrhosis: despite prolonged PT/INR and aPTT, cirrhotic patients have a **relative balance between reduced procoagulants AND reduced anticoagulants**, resulting in a hemostatic equilibrium that is **paradoxically prothrombotic** at the microvascular level. However, **INR >1.5 still increases bleeding risk** and should be corrected. ### Correction Strategy **Vitamin K Deficiency Correction:** - Administer **phytomenadione (vitamin K₁) 10 mg IV daily × 3 days** - Addresses cholestasis-related malabsorption - Effect takes 12–24 hours **Immediate Coagulation Factor Replacement:** - **Fresh frozen plasma (FFP) 10–15 mL/kg** (typically 4–6 units) - Contains all vitamin K-dependent factors (II, VII, IX, X) and factor V - Achieves immediate INR reduction - Target: INR <1.5 before elective procedures **Prothrombin Complex Concentrate (PCC)** — increasingly preferred: - More concentrated than FFP; smaller volume - Faster INR correction - Dose: 25–50 units/kg based on INR and target ### Why Other Options Are Incorrect ```mermaid flowchart TD A[Cirrhotic Coagulopathy<br/>Correction Priority]:::outcome --> B[INR Elevated?]:::decision B -->|Yes - FIRST| C[Vitamin K + FFP/PCC]:::action B -->|No| D[Check other factors] D --> E[aPTT elevated?]:::decision E -->|Mild| F[Correct INR first<br/>aPTT improves with FFP]:::action E -->|Severe| G[Consider FFP]:::action D --> H[Platelets <20,000<br/>or active bleeding?]:::decision H -->|Yes| I[Transfuse platelets]:::action H -->|No| J[Observe; transfuse<br/>only if bleeding]:::action D --> K[Fibrinogen <80 mg/dL?]:::decision K -->|Yes| L[Cryoprecipitate]:::action K -->|No| M[Observe]:::action ``` **High-Yield:** **Prolonged aPTT in cirrhosis improves with FFP/PCC correction of INR** — you do NOT need separate aPTT-directed therapy. The aPTT prolongation reflects the same underlying factor deficiency as the INR. **Platelet Transfusion Threshold:** Transfuse platelets only if count <20,000/μL or <50,000/μL with active bleeding. A count of 45,000/μL does NOT require transfusion unless actively bleeding. (Splenic sequestration means transfused platelets are rapidly pooled into the spleen.) **Fibrinogen Correction:** Fibrinogen of 120 mg/dL is only mildly reduced. Cryoprecipitate is reserved for fibrinogen <80 mg/dL. This patient's fibrinogen does not require correction. ### Clinical Evidence **Key Point:** Multiple guidelines (AASLD, EASL) recommend: 1. **Vitamin K 10 mg IV daily × 3 days** for all cirrhotic patients with coagulopathy 2. **FFP or PCC to target INR <1.5** before invasive procedures 3. **Platelet transfusion only if <20,000/μL or <50,000/μL with active bleeding** 4. **Cryoprecipitate only if fibrinogen <80 mg/dL**